DS1205 (DS-1205b) is a potent AXL kinase inhibitor with anti-lung cancer activity. It inhibits AXL with an IC50 of 1.3 nM. Also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b monotherapy exerted significant antitumor activity in an NIH3T3-AXL allograft model. In an HCC827 xenograft model, combination treatment with DS-1205b and osimertinib significantly delayed on the onset of tumor resistance compared to osimertinib alone in a manner proportional to DS-1205b does. DS-1205b also showed a similar resistance delay effect with erlotinib combination in the same xenograft model.

纯度：≥98%

CAS：1855860-24-0